Before founding Bioxodes, Edmond Godfroid was a long standing senior professor at the University of Brussels (ULB) where he applied his expertise in molecular biology to the discovery of pharmacologically active proteins in the saliva of the Ixodes tick. Dr Godfroid’s and his former team’s work is the basis for the creation of Bioxodes. He received his PhD in Molecular Biology from ULB in 1988 and subsequently acquired post-doctoral experience in the field of Alzheimer’s disease at the Université Catholique de Louvain (UCL). In 1992, he joined Applied Genetics (ULB) where he developed the first PCR-based diagnostic device specific to the tick-borne bacterial pathogen, Borrelia burgdorferi, the causal agent of Lyme disease. In 1995, Dr Godfroid began research on the molecular interaction between Ixodes ticks and their hosts. Until recently he was the Head of the Ectoparasite Molecular Biology Unit at ULB. He has experience of a range of collaborations with academic groups and pharmaceutical companies. Professor Godfroid is a co-founder of Bioxodes.
Pierre Detrixhe is Investment Manager at “Groupe Capital & Croissance”. He manages a fund (“Financière Spin-off Luxembourgeoise”) providing early-stage financings to technological start-ups. Prior to that, he worked as technology transfer officer and scientist in the area of biotechnology. He holds a master in bioengineering and a master in Management.
François Fontaine holds a law degree from the University of Brussels and he is a specialist in Tax affairs. He was counsel in various public institutions and cabinet. He is currently general counsel to the Federal Holding and Investment Company (SFPI)-FPIM. SFPI is focusing its investments on innovative Belgian Companies, hoping to contribute to their financial and societal success story. Mr. Fontaine is also Board member of several companies including biotechs.
Joël Tassignon obtained his PhD in immunology from the University of Brussels (ULB) and a Master in Total Quality Management from the Polytechnic Faculty of the University of Mons. After postdoctoral research on breast cancer at Bordet Institute (Brussels) and on transplantation at Erasme Hospital (ULB, discovery of a new immune-suppressor), he became project manager and lab director of a spin-off from the ULB. He then continued working in the management field as coach in innovation for companies and as director of a laboratory in a Belgian research center acting as a CRO. In parallel to the management of people, projects, technological platforms and laboratories, he was also involved in the management of several types of quality systems as manager and auditor.
Valérie Pireaux obtained her PhD in Biochemistry and Cellular and Molecular Biology (atherosclerosis specialization) from the University of Namur in 2017. After her PhD, she joined Bioxodes as Preclinical Scientist in 2017.
Stéphanie Demoulin obtained her PhD in Biomedical and Pharmaceutical Sciences (Immunology & cancer specialization) from the University of Liege in 2014. After postdoctoral researches on breast cancers at the University of Liège, she became Scientific Writer at Bioxodes in 2016.
Dr Thérèse Croughs has over 30 years experience in the Pharma and Biotech Industry, specializing in the provision of clinical development and regulatory strategy services to manufacturers and developers of biologics and biotech products. She brings a high level of medical expertise in the fields of hematology, immunology, infectious diseases and oncology, as well as experience of clinical development in biotechnology and regulatory affairs, having taken a number of early stage compounds from preclinical to the clinic. Dr Croughs started her career working in R&D for Bayer, NovoNordisk and BioAlliance Pharma, Paris, before joining Cytheris and then Neovacs as CMO. Whilst there, she was responsible for all R&D development activities, including Regulatory Affairs in EU, US as well as ROW. This included the registration of Kogenate® in EU, Loramyc® (miconazole Lauriad) in FR-EU and US/Japan, together with other applications using the same drug delivery technology. She was also responsible for the management of Medical Affairs and R&D and the development of a NCE pipeline (therapies developed to target drug resistance such as small molecules in infectious diseases, gene therapy in oncology).